Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Morbidity and mortality following pelvic ramus fractures in an older Atlantic Canadian cohort

Hamilton CB, Harnett JD, Stone NC, Furey AJ.

Can J Surg. 2019 Aug 1;62(4):270-274.

2.

Research ethics for clinical researchers.

Harnett JD, Neuman R.

Methods Mol Biol. 2015;1281:19-30. doi: 10.1007/978-1-4939-2428-8_2.

PMID:
25694302
3.

Research ethics for clinical researchers.

Harnett JD, Neuman R.

Methods Mol Biol. 2009;473:285-97. doi: 10.1007/978-1-59745-385-1_17. Review.

PMID:
19160745
4.

Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease.

Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE.

J Am Soc Nephrol. 2000 May;11(5):912-6.

5.

Telemedicine and fetal ultrasonography in a remote Newfoundland community.

Reddy ER, Bartlett PJ, Harnett JD, McManamon PJ, Snelgrove C.

CMAJ. 2000 Jan 25;162(2):206-7. No abstract available.

6.

Long-term evolution of cardiomyopathy in dialysis patients.

Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE.

Kidney Int. 1998 Nov;54(5):1720-5.

7.

Mode of dialysis therapy and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, Barre PE.

J Am Soc Nephrol. 1998 Feb;9(2):267-76.

8.

Cardiac disease in diabetic end-stage renal disease.

Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Diabetologia. 1997 Nov;40(11):1307-12.

PMID:
9389423
9.

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Am J Kidney Dis. 1996 Jul;28(1):53-61.

PMID:
8712222
10.

Outcome and risk factors for left ventricular disorders in chronic uraemia.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE.

Nephrol Dial Transplant. 1996 Jul;11(7):1277-85.

PMID:
8672023
11.

The importance of renal impairment in the natural history of Bardet-Biedl syndrome.

O'Dea D, Parfrey PS, Harnett JD, Hefferton D, Cramer BC, Green J.

Am J Kidney Dis. 1996 Jun;27(6):776-83.

PMID:
8651240
12.

Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

J Am Soc Nephrol. 1996 May;7(5):728-36.

13.

Outcome and risk factors of ischemic heart disease in chronic uremia.

Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE.

Kidney Int. 1996 May;49(5):1428-34.

14.

Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE.

Kidney Int. 1996 May;49(5):1379-85.

15.

Hypocalcemia, morbidity, and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE.

Am J Nephrol. 1996;16(5):386-93.

PMID:
8886175
16.

Impact of renal transplantation on uremic cardiomyopathy.

Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD.

Transplantation. 1995 Nov 15;60(9):908-14.

PMID:
7491692
17.

The prognostic importance of left ventricular geometry in uremic cardiomyopathy.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE.

J Am Soc Nephrol. 1995 Jun;5(12):2024-31.

18.

Cardiac function and hematocrit level.

Harnett JD, Kent GM, Foley RN, Parfrey PS.

Am J Kidney Dis. 1995 Apr;25(4 Suppl 1):S3-7.

PMID:
7702071
19.

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS.

Kidney Int. 1995 Mar;47(3):884-90.

20.

Heart failure and ischemic heart disease in chronic uremia.

Parfrey PS, Harnett JD, Foley RN.

Curr Opin Nephrol Hypertens. 1995 Mar;4(2):105-10. Review. No abstract available.

PMID:
7600039
21.

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE.

Kidney Int. 1995 Jan;47(1):186-92.

22.

Cardiac disease in uremia.

Harnett JD, Parfrey PS.

Semin Nephrol. 1994 May;14(3):245-52. Review. No abstract available.

PMID:
8036359
23.

The feasibility and efficacy of early discharge planning initiated by the admitting department in two acute care hospitals.

Parfrey PS, Gardner E, Vavasour H, Harnett JD, McManamon C, McDonald J, Dawe J.

Clin Invest Med. 1994 Apr;17(2):88-96.

PMID:
8004854
24.

Cardiac disease in chronic uremia. Pathophysiology and clinical epidemiology.

Parfrey PS, Harnett JD.

ASAIO J. 1994 Apr-Jun;40(2):121-9. Review. No abstract available.

PMID:
8003748
25.

The management of cardiac disease in chronic uremia.

Parfrey PS, Harnett JD.

Curr Opin Nephrol Hypertens. 1994 Mar;3(2):145-54. Review.

PMID:
7842264
26.

Blood pressure control and regression of LV hypertrophy in dialysis patients.

Harnett JD, Parfrey PS.

Contrib Nephrol. 1994;106:110-3. Review. No abstract available.

PMID:
8174353
27.

Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients.

Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS.

J Am Soc Nephrol. 1994 Jan;4(7):1486-90.

28.

Long-term cardiac morbidity and mortality during dialysis therapy.

Parfrey PS, Harnett JD.

Adv Nephrol Necker Hosp. 1994;23:311-30. Review. No abstract available.

PMID:
8154362
29.

Clinical aspects of cardiomyopathy in dialysis patients.

Parfrey PS, Harnett JD.

Blood Purif. 1994;12(4-5):267-76.

PMID:
7865186
30.

The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients.

Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS.

Nephron. 1993;65(2):212-4.

PMID:
8247182
31.

Predicting glomerular function from adjusted serum creatinine.

Gault MH, Longerich LL, Harnett JD, Wesolowski C.

Nephron. 1992;62(3):249-56. No abstract available.

PMID:
1436333
32.

Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones.

Gault MH, Chafe LL, Morgan JM, Parfrey PS, Harnett JD, Walsh EA, Prabhakaran VM, Dow D, Colpitts A.

Medicine (Baltimore). 1991 Nov;70(6):345-59.

PMID:
1956278
33.

The natural history of myocardial disease in dialysis patients.

Parfrey PS, Harnett JD, Barre PE.

J Am Soc Nephrol. 1991 Jul;2(1):2-12. Review.

34.

Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients.

Parfrey PS, Griffiths SM, Harnett JD, Taylor R, King A, Hand J, Barre PE.

Am J Nephrol. 1990;10(3):213-21.

PMID:
2143353
35.

The clinical course of left ventricular hypertrophy in dialysis patients.

Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, Barre PE.

Nephron. 1990;55(2):114-20.

PMID:
2141918
36.

The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome.

Green JS, Parfrey PS, Harnett JD, Farid NR, Cramer BC, Johnson G, Heath O, McManamon PJ, O'Leary E, Pryse-Phillips W.

N Engl J Med. 1989 Oct 12;321(15):1002-9.

PMID:
2779627
37.

Investigation and management of renal stones.

Barrett BJ, Harnett JD.

Can Fam Physician. 1989 Oct;35:2095-172.

38.

Development of a health questionnaire specific for end-stage renal disease.

Parfrey PS, Vavasour H, Bullock M, Henry S, Harnett JD, Gault MH.

Nephron. 1989;52(1):20-8.

PMID:
2651947
39.

The relationship between hypertension and left ventricular hypertrophy in renal transplant recipients.

Devlin WH, Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Guttmann RD.

Transplant Proc. 1988 Dec;20(6):1221-4. No abstract available.

PMID:
2974203
40.

The spectrum of renal disease in Laurence-Moon-Biedl syndrome.

Harnett JD, Green JS, Cramer BC, Johnson G, Chafe L, McManamon P, Farid NR, Pryse-Phillips W, Parfrey PS.

N Engl J Med. 1988 Sep 8;319(10):615-8.

PMID:
3412378
41.

Congestive heart failure in dialysis patients.

Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barré PE.

Arch Intern Med. 1988 Jul;148(7):1519-25.

PMID:
3382298
42.

The long-term outcome of hepatitis B infection in hemodialysis patients.

Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD.

Am J Kidney Dis. 1988 Mar;11(3):210-3.

PMID:
3344743
43.

Left ventricular hypertrophy in end-stage renal disease.

Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD.

Nephron. 1988;48(2):107-15.

PMID:
2963965
44.

Recurrent hemoperitoneum in women receiving continuous ambulatory peritoneal dialysis.

Harnett JD, Gill D, Corbett L, Parfrey PS, Gault H.

Ann Intern Med. 1987 Sep;107(3):341-3.

PMID:
3619223
45.

Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies.

Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, Guttmann RD.

Transplantation. 1987 Sep;44(3):369-76.

PMID:
2820093
46.

Renal transplantation in primary hyperoxaluria/oxalosis: a report of two cases.

Paul MD, Parfrey PS, Harnett JD, Arbus G, Cohen A, Dancey J, Gault MH.

Transplant Proc. 1987 Aug;19(4):3431-2. No abstract available.

PMID:
3303511
47.

Symptoms in end-stage renal disease: dialysis v transplantation.

Parfrey PS, Vavasour H, Bullock M, Henry S, Harnett JD, Gault MH.

Transplant Proc. 1987 Aug;19(4):3407-9. No abstract available.

PMID:
3303507
48.

Clinical and echocardiographic heart disease in renal transplant patients: prevalence and risk factors.

Harnett JD, Parfrey PS, Griffiths S, Devlin WH, Guttmann RD.

Transplant Proc. 1987 Aug;19(4):3415-8. No abstract available.

PMID:
2956742
49.

Erythromycin-cyclosporine interaction in renal transplant recipients.

Harnett JD, Parfrey PS, Paul MD, Gault MH.

Transplantation. 1987 Feb;43(2):316-8. No abstract available.

PMID:
3544392
50.

Low-output left ventricular failure in end-stage renal disease.

Parfrey PS, Harnett JD, Griffiths S, Gault MH, Barre PE, Guttmann RD.

Am J Nephrol. 1987;7(3):184-91.

PMID:
3307413

Supplemental Content

Loading ...
Support Center